 |
Specialty Molecular Division |
One of our exciting new areas of expertise is sequencing,
in line with this we now offer of HIV-1 drug resistance testing using either ViroSeq
(FDA Approved) or a published and extensively used In-house Assay (Wallis et al., 20101 ).
The in-house assay starts with an automated viral RNA extraction followed by a RT-PCR
and sequencing the entire protease and partial reverse transcriptase (RT1-250).
Unlike, the ViroSeq assay (which was initially designed for HIV-1 subtype B and
therefore a high “no amplification” rate is observed in HIV-1 subtype C),
the in-house assay has been designed for HIV-1 subtype C, and has also been
evaluated in subtype A, D, AG and several circulating recombinants
(Price et al., 20102 ; Wallis et al., 20101, Hamers et al., 20113).
Apart from the above mentioned assay we are also able to offer HIV sequencing of:
- Only Reverse transcriptase region (RT 1-250);
- Integrase sequencing;
- Full-length sequencing of the reverse transcriptase region (several studies are starting to emerge linking
mutations developing in the RNase H and connection domains of polymerase to the antiretroviral resistance [Brehm et al., 20104 ; Wallis et al., 20115 ]).
If you would like further information about the TB facility
please feel free to contact us.
1Wallis CL., et al . Affordable in-house antiretroviral drug resistance assay with good performance in HIV-1 subtype C. J Virol Methods. 2010 Feb;163(2):505-8.
2Price MA, Wallis C, et al., and the IAVI Early Infection Cohort Study Group Increasing transmitted HIV-1 drug resistance in east and southern Africa.
AIDS Research and Human Retroviruses. 2010, 26, (11).
3Hamers RL, Wallis CL, et al., for PharmAccess African Studies to Evaluate Resistance (PASER). HIV-1 drug resistance in antiretroviral-naive individuals
in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis. 2011 Jul 27.
4Brehm J, Wallis CL, et al., . Frequent Emergence of N348I in the Connection Domain of Reverse Transcriptase with Virologic Failure of First-Line NNRTI-Containing Regimens in South Africa.
Antiviral Therapy 2010; 15 Suppl 2: A126.
5Wallis C, R Viana, et al., Mutations in the Connection and RNAse H Domains of Reverse Transcriptase after Exposure to sdNVP to Prevent MTCT in South Africa. CROI, Boston USA, 2011.
|